October 21-22, 2025 | Liverpool, UK
Pelago Bioscience is pleased to participate in ELRIG Drug Discovery 2025, taking place on October 21–22 in Liverpool, UK.
Visit us at Booth #F07 to meet Isabel Martin Caballero (Project Advisor), Helena Almqvist (Global Key Account Manager), Chandra Chirumamilla (Senior Scientist), and Aditi Kallai (Associate Scientist). Our team will be available to discuss how CETSA® technology provides biologically relevant insights to guide decision-making across small molecule drug discovery.
Technology Spotlight Presentation
Title: Proteome-wide CETSA profiling at Pelago Bioscience
Presenter: Isabel Martin Caballero
Date & Time: October 22, 14:30–14:35
Track: Chemical biology and ‘omics for small molecules – technologies, developments and learnings
Poster Presentations
1. Integrating Degradation, Engagement, and Selectivity: CETSA® as a Framework for Degrader Validation
Presenter: Isabel Martin Caballero
Schedule:
- October 21, 12:45–14:00
- October 22, 12:50–14:00
Overview:
Protein degradation allows targeting of previously undruggable proteins. Yet, not all degrader-bound proteins are degraded. This study shows how CETSA® helps explore PROTAC pharmacology by combining antibody-based detection and MS readouts to assess binding and degradation across the proteome.
2. Identification of novel p53 modulating compounds through rapid high-throughput CETSA® screening
Presenters: Chandra Chirumamilla and Aditi Kallai
Location: Booth #F07
This poster highlights how CETSA® can be applied in high-throughput screening to identify novel compounds modulating p53 activity, delivering functional cellular data that supports hit validation and mechanism-of-action studies.
We look forward to connecting with scientists and innovators at ELRIG Drug Discovery 2025 to discuss how CETSA® can support degrader research, target engagement profiling, and lead optimization.
Learn more about the event here